Cart
sales@molnova.com
Hypocretin (70-98) (human)
CAS No. 1129545-33-0
Hypocretin (70-98) (human)( ——— )
Catalog No. M42154 CAS No. 1129545-33-0
Hypocretin (70-98), human is a polypeptide that is capable of binding to an orexin receptor OX1R and promotes apoptosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameHypocretin (70-98) (human)
-
NoteResearch use only, not for human use.
-
Brief DescriptionHypocretin (70-98), human is a polypeptide that is capable of binding to an orexin receptor OX1R and promotes apoptosis.
-
DescriptionHypocretin (70-98), human is a polypeptide that is capable of binding to an orexin receptor OX1R and promotes apoptosis.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptorhuman OX1R
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number1129545-33-0
-
Formula Weight2957.4
-
Molecular FormulaC125H214N44O37S
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bruno Robert, et al. Polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor. Patent WO2017140845A1.
molnova catalog
related products
-
1,3-Dihydroxy-2,7,8-...
6,8-Dihydroxy-1,2,7-trimethoxy-3-methylanthraquinone (compound 1) is an anthraquinone α-glucosidase inhibitor (IC50:185 μM), which can be isolated from Cassia seeds.
-
Cardiotoxin Analog (...
Cardiotoxin Analog (CTX) IV (6-12) (TFA) is a part peptide of Cardiotoxin Analog (CTX) IV. Cardiotoxin analogues IV isolated from the venom of Taiwan Cobra. CTX IV is an unique snake venom cardiotoxin.
-
Ziftomenib
Ziftomenib (KO-539) is an inhibitor of menin-MLL interaction with antitumor activity, suitable for leukemia research.
